Election committee for Vitrolife AB (publ)

Election committee for Vitrolife AB (publ)

The following people have been appointed as members of Vitrolife's election
committee for the Annual General Meeting in 2009:

Henrik Blomquist, representing Skanditek Industriförvaltning
Johan Ståhl, representing Lannebo Fonder
Henrietta Theorell Malmsäter, representing SEB Fonder
Patrik Tigerschiöld, Chairman of the Board


The appointments have been made in accordance with the instructions regarding
principles for the appointment of the company election committee which were
determined at the Annual General Meeting of Vitrolife on May 10, 2005. 

The Annual General Meeting of Vitrolife AB (publ) will be held on April 27, 2009
in Gothenburg. 

Shareholders who wish to have an item considered at the Annual General Meeting
can submit a request to the Board to this effect. Such a request for an item to
be considered is to be sent to Vitrolife AB (publ), Att: Chairman of the Board,
Box 9080, 400 92 Gothenburg (as from November 1, 2008), and must have been
received by the Board no later than seven weeks before the Annual General
Meeting, or otherwise in such good time that the matter, where necessary, can be
included in the notice to attend the Annual General Meeting.


October 6, 2008
Kungsbacka, Sweden

Vitrolife AB (publ)




Queries should be addressed to: 
Patrik Tigerschiöld, Chairman of the Board, phone +46 8 614 00 20.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

The information in this press release is such as that which Vitrolife is
required to publish in accordance with the Securities Exchange and Clearing
Operations Act. The information was submitted for publication on October 6, 2008
at 4.00 pm.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.